Discover the extraordinary potential of chlorine dioxide in healthcare, understand its mechanisms within the body, and explore its effectiveness in treating a variety of illnesses.
Live Last read · last published · next check
Saves to your Listen queue, to pick up on another day or another device.
Oncology already knows repeatability wins — it is why systemic therapy dominates advanced cancer. Local therapy has never had a repeatable member. Intratumoral chlorine dioxide may be the first.
Repeat Intratumoral ClO₂ Dosing in a Dog That Had Already Lost Its Tongue
Four signals from the new North American liver cancer consensus — and what they mean for intratumoral chlorine dioxide ablation
Since filing for FDA Orphan Drug Designation for glioblastoma on April 8, we have steadily added to the evidence base behind the intratumoral ClO₂ ablation system — more veterinary tumor cases, and a closer look at how fast and how completely the reaction self-limits, most recently in whole blood.
Why the EU’s Article 59 exception matters for advanced cancer patients, and why we believe an intratumoral chlorine dioxide ablation system qualifies under it
What happens when chlorine dioxide enters a blood-rich environment?
A benchtop observation on reaction speed and self-limitation in liquid porcine blood
Intratumoural chlorine dioxide ablation versus surgery — starting with the dimension where surgery wins
Why naturally occurring animal tumors may provide stronger early evidence for intratumoral chlorine dioxide ablation than an early human trial
When a dog is diagnosed with an oral tumor—especially one involving the mouth, gums, or tongue—owners usually face the same difficult questions.
FDA’s new early-stage development policies are moving in a direction that fits unusually well with the evidence already accumulated for Intratumoral Chlorine Dioxide Therapy
Twenty Minutes After Treatment — Chaozhou, Guangdong, China · August 13, 2026
What Three Veterinary Cases May Reveal About a Different Way of Destroying Cancer
